AstraZeneca-Daiichi Breast Cancer Drug Gets Approval in England
England’s health watchdog, NICE, has recommended Enhertu as a treatment option for breast cancer within the National Health Service. The drug is developed jointly by AstraZeneca and Daiichi Sankyo. The endorsement follows an evaluation of its clinical effectiveness and cost-effectiveness in treating HER2-positive advanced or metastatic breast cancer. This decision could significantly expand access to Enhertu, which has already been approved in other major markets like the U.S., Japan, and parts of Europe. This approval is a key milestone for both AstraZeneca (AZN) and Daiichi Sankyo (DSNKY), as it validates their investment in oncology innovation and could lead to increased sales within one of the world’s largest public healthcare systems.
